Portugal access delays remain a defining challenge for health systems seeking to balance innovation with fiscal responsibility. The average interval of 839 days between European authorisation and national reimbursement creates significant consequences for how value is assessed and resources are allocated. Decision-makers in health economics and market access must consider how these timelines affect the assumptions that underpin pricing strategies and long-term budget planning.

Understanding the Economic Consequences

Extended evaluation periods erode the modelled benefits that health technology assessment bodies rely upon when reaching reimbursement decisions. When patients wait more than two years for funded treatment, projected gains in quality-adjusted life years and reductions in downstream care costs lose accuracy. This misalignment complicates efforts to apply value-based pricing frameworks and increases uncertainty in budget impact analyses prepared for national payers.

Implications for Market Access and Pricing

The persistence of hospital-level negotiations after central assessment further fragments market access. Each additional layer of review extends timelines and generates inconsistent coverage across regions. For pharmaceutical companies, this environment demands pricing strategies that account for staggered adoption and variable revenue realisation. Payers, meanwhile, face difficulties in forecasting expenditure when decisions remain decentralised.

System Dynamics and Policy Implications

Early access programmes, intended as temporary bridges, have become routine responses to slow central processes. While they provide interim options for patients with severe conditions, their hospital-specific nature limits the generation of consistent data needed for subsequent reimbursement decisions. A shift toward nationally coordinated mechanisms could improve predictability for both industry and health systems, supporting more reliable budget impact projections and clearer pathways to value-based pricing agreements.

Recommendations for Decision-Makers

Companies should prepare economic models that can be updated rapidly once centralised data platforms become operational under revised national assessment procedures. Health technology assessment bodies could publish explicit evidence requirements and timelines to allow sponsors to align clinical development and real-world evidence collection more effectively. Payers would benefit from defining clear transition criteria from early access into routine reimbursement, converting ad-hoc expenditure into planned budget lines. Health systems should accelerate implementation of unified electronic records to improve patient identification for both clinical research and equitable treatment allocation.

These Portugal access delays illustrate that the principal barrier is not the availability of innovative medicines but the speed and consistency with which their value is recognised. Coordinated reform of assessment processes and negotiation structures offers the most direct route to aligning therapeutic innovation with sustainable healthcare financing.

This reflection draws on the interview Paulo Gonçalves in the May 2026 edition of e•PHARMA ( https://www.apifarma.pt ).

Table of Contents